CLL Video Channel
Explore the latest insights and summaries from experts in CLL.
Therapeutic Agents
Massachusetts General Hospital Cancer Center
Practice-Changing Updates in Indolent B-Cell Lymphomas
FEATURING
Jake Soumerai
- 469 views
- June 5, 2024
- 1
Cleveland Clinic Taussig Cancer Institute
R/R CLL/SLL: Overcoming Resistance to Covalent BTKi and/or BCL2 Inhibitors
FEATURING
Brian Hill
- 53 views
- June 25, 2024
Insights from 2024 EHA Annual Meeting
EHA 2024 Insights: Advantages of Using Venetoclax-Based Therapy in High-Risk CLL
FEATURING
Catherine Coombs
- 87 views
- June 28, 2024
- 1
City of Hope
Venetoclax vs. BTKis in CLL Treatment
FEATURING
Alexey Danilov
- 255 views
- June 28, 2024
- 1
Insights from 2024 EHA Annual Meeting
EHA 2024 Insights: Sonrotoclax + Zanubrutinib in R/R CLL/SLL
FEATURING
Stephen S. Opat
- 53 views
- July 3, 2024
Saad Kenderian
Liso-Cel in CLL: Summary of FDA Approval and Guidance on Toxicity Management
- 128 views
- July 8, 2024
- 1
SOHO Brazil 2024
3L in CLL: The Best Options in a Patient Double-Refractory to Covalent BTKi and to BCL-2 Inhibitor
FEATURING
Jan Burger
- 502 views
- July 11, 2024
- 1
UChicago Medicine
The Next Frontier of Targeted Therapy in Lymphoma
FEATURING
Kami Maddocks
- 238 views
- July 22, 2024
UChicago Medicine
Exploring the Value of PI3K in Lymphoma Treatment
FEATURING
Changchun Deng
- 18 views
- July 22, 2024
UChicago Medicine
Targeting BTK in B-Cell NHL: Pros and Cons of Inhibitors and Degraders
FEATURING
Adam Kittai
- 48 views
- July 22, 2024
- 1
XV Eurasian Hematology-Oncology Congress - EHOC 2024
Venetoclax + Ibrutinib as 1L Treatment in Patients With CLL: Meta-Analysis of RCTs
FEATURING
Ahmet Sarici
- 31 views
- August 15, 2024
MyCancerHaven
Experts Discuss Recent Developments in CLL
FEATURING
Ravi Vij,
Dahlia Sano
- 70 views
- August 30, 2024
XV Eurasian Hematology-Oncology Congress - EHOC 2024
Debates in CLL: Continuous or Finite Duration Therapy
FEATURING
Nitin Jain
- 166 views
- October 6, 2024
NYU Langone
Long-Term Efficacy of Ibrutinib in CLL
FEATURING
Marc Braunstein
- 78 views
- October 6, 2024
XV Eurasian Hematology-Oncology Congress - EHOC 2024
Novel Agents in the Treatment of R/R CLL
FEATURING
Nitin Jain
- 44 views
- October 9, 2024
Cleveland Clinic Taussig Cancer Institute
Updates in CLL From ASH 2023
FEATURING
Allison Winter
- 88 views
- October 22, 2024
Northwestern Medicine Oncology and Hematology
Pirtobrutinib in R/R CLL: Most Recent BRUIN Trial Results
FEATURING
Shuo Ma
- 38 views
- October 29, 2024
City of Hope
Incorporating Pirtobrutinib and CAR-T Therapy Into CLL Practice
FEATURING
Alexey Danilov
- 43 views
- November 12, 2024
University of Colorado Division of Hematology
Summary and Practice Impacts of Recent Updates in B-Cell Lymphomas
FEATURING
Manali Kamdar
- 252 views
- April 8, 2024
- 1
Indy Hematology Review
State of the Art in 2024: Emerging Therapies in Hematologic Malignancies
FEATURING
Ruemu Birhiray
- 915 views
- April 16, 2024
- 5
Constantine Tam
R/R CLL: A Matching-Adjusted Indirect Comparison of Zanubrutinib vs. Acalabrutinib
- 315 views
- April 22, 2024
Indy Hematology Review
CLL: Evaluating and Therapeutic Approaches for the Management of the R/R Patient
FEATURING
Jennifer Woyach
- 295 views
- April 23, 2024
- 1
MyCancerHaven
CLL and MCL: Experts Discuss the Use of Pirtobrutinib
FEATURING
Ravi Vij,
Geoffrey Shouse
- 240 views
- May 7, 2024
- 2
Yale Cancer Center
Yale Cancer Center Updates on B-Cell Lymphomas: Exploring MCL, DLBCL, FL, and CLL/SLL
FEATURING
Shalin Kothari
- 132 views
- May 13, 2024
Manfred Welslau
Ibrutinib for CLL: The Importance of Adherence in Optimizing Efficacy
- 246 views
- May 21, 2024
Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient
Practical Updates on Advances in CLL and MCL
FEATURING
Elise Chong
- 269 views
- March 13, 2024
- 1
Scripps Health
Updates in CLL: Treatment for BTKi-Refractory and BTKi/BCL-2i-Refractory Disease
FEATURING
Susan O'Brien
- 243 views
- March 18, 2024
Fred Hutchinson Cancer Center
FDA Approval of Liso-Cel in R/R CLL: What You Need to Know
FEATURING
Mazyar Shadman
- 149 views
- March 26, 2024
Lydia Scarfò
Managing Cardiotoxicities in BTKi Treatment for CLL: Atrial Fibrillation and Atrial Flutter
- 87 views
- October 15, 2024
Avirup Guha
Managing Cardiotoxicities in TKI Therapy for CLL: Atrial Fibrillation and Atrial Flutter
- 80 views
- October 23, 2024
Nicole Lamanna
Pirtobrutinib in CLL: Current and Potential Utility in the Treatment Landscape
- 89 views
- December 3, 2024
Fox Chase Cancer Center
Pirtobrutinib in R/R B-Cell Malignancies: Newest Data From the BRUIN Trial
FEATURING
Shazia Nakhoda
- 17 views
- December 13, 2024
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: Acalabrutinib, Venetoclax, Obinutuzumab in a 1L CLL Enriched for High-Risk Disease
FEATURING
Matthew Davids
- 17 views
- December 13, 2024
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: Ibrutinib or Acalabrutinib in CLL - Impact of Dose Reduction on Therapy Duration
FEATURING
Mazyar Shadman
- 25 views
- December 17, 2024
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: Zanubrutinib in Acalabrutinib-Intolerant Patients With B-Cell Malignancies
FEATURING
Mazyar Shadman
- 60 views
- December 18, 2024
- 1
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: Sonrotoclax + Zanubrutinib in 1L CLL - Results From the BGB-11417-101 Study
FEATURING
Jake Soumerai
- 9 views
- December 20, 2024
